Collegium Pharma (COLL) Appoints Nancy S. Lurker to its Board

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025.

“Collegium is pleased to welcome Nancy to our Board of Directors,” said Mike Heffernan, Founder and Chairman of the Board of Collegium. “Nancy’s expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.”

“This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth following its recent expansion into the neuropsychiatry market,” said Ms. Lurker. “I look forward to collaborating with Collegium’s Board to advance the Company’s mission.”

Ms. Lurker most recently served as President and Chief Executive Officer of EyePoint Pharmaceuticals, Inc. until 2023, when she transitioned to the role of Executive-Vice Chair of its Board of Directors. Prior to EyePoint, Ms. Lurker was President, CEO and Board Director of PDI, Inc., a Nasdaq-listed healthcare commercialization company, which sold to Publicis Health. Before joining PDI, she served as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals and as President and CEO of ImpactRx, Inc.

In addition to her Board appointments at Collegium and EyePoint, Ms. Lurker serves on the Board of Directors of Alkermes plc and Altasciences, LLC. She also serves on Advisory Boards for Novo Holdings and for Stanford Medicine’s Master of Science in Translational Research and Applied Medicine program. She has previously held positions on the Boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, ConjuChem and ImpactRx.

Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville.

You May Also Be Interested In

• NNN REIT adds two directors amid board succession planning
• Deluxe names Celero Commerce founder as Merchant Services president
• Lifetime Brands closes $60M term loan and extends $200M credit facility